Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for some time ...

Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's fourth-quarter earnings call. The company reported solid fourth-quarter results, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Considering this and Viking's clinical trial advancements, is the stock a buy right now? Image source: Getty Images. First, let's back up and take a look at the company's story over the past year.

Both Viking and Roche are attempting to horn in on this market ... The companies plan to sell it both separately and in combination with Roche's CT-388 incretin drug. Image source: Getty Images. Both ...

Photo Credit: Viking Viking Holdings told investors Tuesday ... from the revaluation of warrants issued by Viking due to stock price appreciation. The ocean side of the business has 87% of 2025 ...

Gerard Bottino / SOPA Images / LightRocket via Getty Images Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's fourth-quarter ...

The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.